BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

4SC AG 

Am Klopferspitz 19a

Martinsried    82152  Germany
Phone: 49-0-89-7007630 Fax: 49-0-89-700763-29


SEARCH JOBS


Industry
Biotechnology






 Company News
4SC AG (VSC.F) in Talks With 3 Potential Partners for Cancer Drug 9/13/2012 8:00:37 AM    More...
4SC AG (VSC.F) Says Its Resminostat Meets Primary Endpoint In Phase II Trial 1/19/2012 11:00:19 AM    More...
4SC AG (VSC.F)'s Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat Hodgkin's Lymphoma 10/13/2011 10:21:46 AM    More...
4SC AG (VSC.F)'s Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma 9/26/2011 9:36:52 AM    More...
4SC AG (VSC.F)'s Resminostat Meets Primary Efficacy Endpoint in Phase II Trial in Hodgkin's Lymphoma (HL) 9/6/2011 6:46:24 AM    More...
FDA Grants Orphan Drug Designation to 4SC AG (VSC.DU)'s Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma 7/12/2011 9:47:27 AM    More...
4SC AG (VSC.DU) Says Vidofludimus Trial Missed Primary Efficacy Endpoint In RA 6/10/2011 7:12:13 AM    More...
4SC AG (VSC.DU): Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model 5/27/2011 11:05:16 AM    More...
Arthritis Drug's $1.4 Billion Promise for German Drugmaker 4SC AG (VSC.DU) Hinges on Study, Could Present Itself as Pfizer Inc. (PFE)'s Main Oral RA Competition 5/27/2011 7:23:12 AM    More...
4SC AG (VSC.DU) Presents Final Phase IIa Data on Vidofludimus in Inflammatory Bowel Disease Study at the 6th ECCO IBD Conference 2/28/2011 9:06:59 AM    More...
1234

//-->